Distilled water versus 0.9% saline as the solvent for a single immediate intravesical instillation of mitomycin C after transurethral resection of non-muscle-invasive bladder cancer: a prospective comparative study

Bladder cancer often begins as a shallow growth on the inner lining of the bladder, a condition that doctors can usually remove with a scope passed through the urethra. While the surgery successfully clears the visible tumor, the procedure itself leaves behind microscopic cells that have floated loose in the urine. These stray cells are dangerous because, within hours, they can stick to the raw, healing surface of the bladder and grow into new tumors, causing the cancer to return. To stop this, surgeons often wash a chemotherapy drug into the bladder immediately after surgery to kill these floating cells before they can reattach. For decades, the liquid used to mix this drug has been treated as a simple, neutral carrier, much like water used to dissolve a pill. However, the chemical nature of that liquid might be far more important than anyone realized, potentially acting as a weapon in its own right.

A team of researchers in Istanbul set out to test whether the choice of liquid matters when delivering this chemotherapy. They focused on a specific drug called mitomycin C, which is standard for preventing recurrence, and compared two different solvents: sterile distilled water and the standard saltwater solution known as saline. The logic behind the experiment was rooted in physics rather than just chemistry. Cells in the human body are designed to exist in a salty environment. If you place a cell in pure distilled water, which lacks salt, water rushes into the cell to balance the difference, causing it to swell and burst. The researchers hypothesized that if they used distilled water to mix the chemotherapy, the liquid itself would lyse, or burst, any floating cancer cells before the drug even had a chance to work, adding a second layer of protection to the treatment.

To investigate this, the team followed eighty-six patients who had just undergone surgery to remove their bladder tumors. The patients were not assigned to groups by a random coin toss, but rather by the time period in which they were treated. One group received the chemotherapy drug dissolved in forty milliliters of sterile distilled water, while the other group received the exact same dose of the drug dissolved in forty milliliters of standard saline. In both cases, the fluid was held in the bladder for two hours before being drained. The researchers then watched these patients closely for up to five years, checking for the return of cancer through regular camera examinations of the bladder.

The results were striking and ran counter to what the researchers expected based on the starting conditions of the patients. The group that received the distilled water mixture had a significantly lower rate of cancer returning. Only five out of thirty-four patients in the distilled water group saw their cancer come back, a rate of about fifteen percent. In contrast, thirty-two out of fifty-two patients in the saline group experienced a recurrence, a rate of roughly sixty-two percent. This difference was so large that the researchers calculated that for every two patients treated with distilled water instead of saline, one recurrence could be prevented. This outcome was particularly surprising because the distilled water group actually started with a higher risk profile; nearly eighty percent of those patients had multiple tumors, whereas only about one-third of the saline group had more than one. In bladder cancer, having multiple tumors is a known predictor that the disease is more likely to return, yet the distilled water group still fared far better.

The study also looked at whether the cancer became more aggressive or spread deeper into the bladder wall, a process known as progression. Here, the numbers were smaller and less definitive, with one patient in the distilled water group and five in the saline group showing signs of progression, a difference that did not reach statistical significance. However, the safety profile of the distilled water was excellent. No patients in either group suffered from chemical irritation of the bladder, skin reactions, or other complications related to the treatment. The distilled water did not cause harm, even though it is a substance that would burst a cell in a petri dish, suggesting that the bladder can tolerate the brief exposure without injury.

The authors suggest that the success of the distilled water likely comes from a combination of factors. First, the low salt content of the water may have physically destroyed the floating cancer cells through osmotic pressure, a process that happens instantly and does not depend on the cells dividing. Second, the drug itself might have been more effective because it dissolves more completely in distilled water than in saline, ensuring that the full dose reached the bladder lining. The researchers acknowledge that because the study was not a randomized trial, where patients are assigned by chance, there is a possibility that other unseen factors influenced the results. The difference in outcomes was so large that it could be a sign of a major breakthrough, or it could be due to subtle differences in how the surgeries were performed or how the patients were monitored during the different time periods.

Despite the need for further confirmation, the findings offer a compelling new perspective on a routine medical procedure. The study indicates that the liquid used to deliver bladder cancer medication is not an inert bystander but an active participant in the treatment. Using distilled water appears to turn the solvent into a partner in the fight against cancer, destroying loose cells and potentially delivering the drug more effectively, all without adding cost or risk. While the medical community waits for a definitive randomized trial to confirm these results, the data suggests that a simple change in the mixing fluid could significantly alter the course of the disease for many patients.